Skip to content

Released Nov 4, 2026, after the close

10-Q filed Nov 4, 2026, 35 days after period end · 0001628280-26-070259

Q3 2026 · 10-Q
Revenue$53.23M+1.8% vs Q3 2025+10.6% vs Q2 2026
Net Income-$6.10MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.05N/M vs Q3 2025N/M vs Q2 2026
Gross Profit$31,206,000+13.3%
Operating Income-$8,423,000N/M
Operating Cash Flowderived-$4,451,000N/M
Free Cash Flowderived-$5,958,000N/M
Margins · derived
Gross margin58.6%+5.9 pt vs Q3 2025
Operating margin-15.8%+1.8 pt vs Q3 2025
Net margin-11.5%−1.0 pt vs Q3 2025

What the release said

Total revenue for the third quarter of 2026 was $53.2 million, a 2% increase compared to the third quarter of 2025.

Cytek Biosciences reported total revenue of $53.2 million for the third quarter of 2026, a 2% increase compared to the third quarter of 2025.12

GAAP gross profit was $31.2 million for the third quarter of 2026, a 13% increase, with GAAP gross profit margin of 59% compared to 53% in the third quarter of 2025.3

Operating expenses were $39.6 million for the third quarter of 2026, and net loss was $6.1 million compared to a net loss of $5.5 million in the third quarter of 2025.45

Cytek Biosciences is maintaining the midpoint of its full year 2026 revenue outlook and narrowing the range to $208 million to $211 million, assuming no change in current foreign currency exchange rates.6

Cash, cash equivalents, restricted cash and marketable securities totaled $256.3 million as of September 30, 2026, compared to $262.0 million as of June 30, 2026.7

Total revenue, third quarter 2026
$53.2 million Compared to the third quarter of 2025, a 2% increase1
GAAP gross profit, third quarter 2026
$31.2 million A 13% increase compared to the third quarter of 20253
Net loss, third quarter 2026
$6.1 million Compared to a net loss of $5.5 million in the third quarter of 20255
Full year 2026 total revenue outlook
$208 million to $211 million Range narrowed; midpoint maintained, assuming no change in current foreign currency exchange rates6
Cash, cash equivalents, restricted cash and marketable securities
$256.3 million As of September 30, 2026, compared to $262.0 million as of June 30, 20267
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$53.23M$52.29M$51.50M$48.00M
Net Income-$6.10M-$5.48M$941.00K-$6.46M
EPS Diluted-$0.05-$0.04$0.01-$0.05

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR